Drugs /

vinorelbine

Back to Drugs List

Overview

Generic Name(s):
vinorelbine
Trade Name(s):
Eunades, Navelbine, and Biovelbin
NCI Definition [1]:
A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.

Clinical Trials

View Clinical Trials for vinorelbine

Vinorelbine has been investigated in 33 clinical trials, of which 25 are open and 8 are closed. Of the trials investigating vinorelbine, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), 5 are phase 1/phase 2 (3 open), 13 are phase 2 (12 open), and 12 are phase 3 (9 open).

HER2 Positive, ERBB2 Amplification, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for vinorelbine clinical trials.

Breast carcinoma, non-small cell lung carcinoma, and alveolar rhabdomyosarcoma are the most common diseases being investigated in vinorelbine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vinorelbine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vinorelbine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vinorelbine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Navelbine, Biovelbin, Eunades, navelbine ditartrate, vinorelbinum, vnb, vinorelbine [chemical/ingredient], vinorelbine, vinorelbine (product), nor-5'-anhydrovinblastine, vinorelbine, 5'-nor-anhydrovinblastine, 5'-nor-anhydrovinblastine, vinorelbina, c'-norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-, nor-5'-anhydrovinblastine, vinorelbine (substance), dihydroxydeoxynorvinkaleukoblastine, 3',4'-didehydro-4'-deoxy-c'-norvincaleukoblastine, 5'-noranhydrovinblastine, vinorelbin, 608210, nvb
Drug Categories [2]:
Antimicrotubule agents
NCIT ID [1]:
C1275
SNOMED ID [1]:
F-615D3

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.